About Wonderlab Bio

Building the cells
medicine has been
waiting for.

A regenerative-medicine company based in Boston. Founded to close the gap between what cell therapy can do in theory and what patients can actually receive.

01 / 04

What we
are building

Mission and principles.

Cell therapy has been promising the same thing for thirty years. Our work is about whether it can actually be delivered to the patients it was supposed to help.

Wonderlab Bio exists to close one of medicine's longest-standing gaps. Cell therapies can repair damaged tissue, reverse degenerative disease, and restore function. The field has known this for thirty years. Manufacturing complexity, immune rejection, and cost have kept the treatments inside research hospitals and away from most of the people who could benefit from them.

We built the first fully characterized HLA-matched allogeneic iPSC cell bank in the world to change that arithmetic. By matching the donor's immune signature to the patient's, the body accepts the cells without immunosuppression. The cells can be manufactured ahead of demand. The cost can be brought down to a level that makes treatment of chronic conditions practical, not exceptional.

The first three programs are in osteoarthritis, cardiac disease, and neurodegeneration. Each was chosen because the unmet need is large, because cell therapy offers a mechanism existing treatments do not have, and because the path from the laboratory to the patient is realistic rather than hypothetical.

Mission

Develop regenerative medicine that extends the quality years of human life. Pick the programs where the science is real, the unmet need is largest, and the manufacturing path is honest.

Principles

We pick programs by impact per research dollar, not by how interesting they sound. We use the same cell bank across every program because that is what the platform is for. We do not promise patients anything we are not willing to ship to our own family.

27 Drydock Ave

2nd Floor, Boston, MA 02210

Seaport

Boston Innovation District

02 / 04

Founding
leadership

The team.

Three people lead the company. One founder, two principal scientists.

Robin Smith

Founder and CEO

Robin has spent twenty-nine years building life sciences companies from founding through exit. At Synthematix he invented the electronic laboratory notebook. He then founded ArtusLabs, one of the first big-data companies in life sciences, which was acquired by PerkinElmer. He stayed on at PerkinElmer as a Vice President overseeing a $120M annual R&D budget and a team of more than five hundred engineers and scientists. Across that career he has raised more than $60M in venture capital, was an EY Entrepreneur of the Year finalist for New England in 2018, and is the named inventor on twenty-three patents covering biotechnology, diagnostics, and artificial intelligence.

Filipa Pinto, Ph.D.

Principal Scientist

Stem cell biologist with a background that spans physics, computational science, and regenerative biology. Filipa's early work on the transcription factor p63 and its role in epithelial stem cell self-renewal was published in Cell. She trained in John Gearhart's laboratory at Penn's Institute for Regenerative Medicine, where she generated iPSCs across multiple species and developed differentiation protocols for osteogenic, chondrogenic, and cardiomyocyte lineages. At Boston University, she showed that suppression of TGF-B enables long-term expansion of epithelial stem cells without immortalization. At Wonderlab she directs allogeneic iPSC line development and mesenchymal differentiation for therapeutic applications.

Deepti Jain, Ph.D.

Head of QC Operations

Molecular biologist with more than fifteen years of multidisciplinary work spanning genomics, RNA biology, proteomics, and stem cell research across academic and industry roles in India, Korea, Singapore, and the United States. Deepti earned her Ph.D. in molecular biology from JNU University, where she investigated stress-responsive gene regulation. As a DST Inspire Faculty awardee at Delhi University she established a Protein Biology Laboratory and mentored doctoral researchers. In industry, she held senior scientific roles at GrapheneDx and LexaGene developing molecular diagnostic and assay platforms. At Wonderlab she co-leads iPSC and MSC differentiation protocol development and manages the genomic, phenotypic, and quality control workflows that operate under GMP and GLP rules.

03 / 04

Founder
track record

Why Wonderlab exists.

The work that built Wonderlab did not happen overnight. The cell bank, the IP, and the regulatory strategy are the product of a career of building, scaling, and exiting life sciences companies.

Robin's career has been built at the intersection of life sciences and software. At Synthematix he invented the electronic laboratory notebook, an idea that changed how scientists document and share research. He then founded ArtusLabs, one of the first big-data companies in the field, which pioneered unstructured-data understanding for pharmaceutical research. PerkinElmer's acquisition of ArtusLabs reflected the strategic value of that work, and Robin stayed on to lead informatics across a global R&D organization.

He went on to build a precision-medicine platform that combined biobanking, molecular diagnostics, and consumer genomics. During the COVID-19 pandemic the team earned the thirteenth Emergency Use Authorization issued by the FDA and operated one of the first automated COVID testing centers in the country. The growth and acquisition of that company gave Robin both the operational experience and the foundational biobank that became the working core of Wonderlab Bio.

Wonderlab is the natural endpoint of that work. The cell bank, the IP portfolio, the regulatory strategy, and the team are all the result of lessons learned over a career. The goal now is to give regenerative medicine a foundation it can actually run on, at the scale and consistency clinical use will demand.

Years in life sciences

Granted patents

$60M⁺

Raised over career

500⁺

Scientists managed